Roboearth – Lifestyle
Author:
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
May 8, 2026
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 8, 2026
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
May 8, 2026
Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
March 10, 2026